What is this study about?
This study is an open-label extension of the Phase 2b clinical trial called KHENERGYZE where participants will receive Sonlicromanol (KH-176) for approximately 1 year.
The aim of this study is to examine long-term safety and explore long-term efficacy of this medication.
Who can take part?
This is an international, multi-centre study for those who previously participated in the KHENERGYZE Phase 2b trial. The recruitment therefore is currently open by invitation only.
What's involved in taking part?
The study aims to assess safety of Sonlicromanol (KH-176) and its effect on cognitive performance, mood, headaches, quality of life and physical performance.
Where is the study taking place?
This is an international study with the sites located in Denmark, Germany, Netherlands and the UK. The UK site is located in Newcastle upon Tyne.
How do I find out more?
If you are interested in knowing more about the study please contact Isabel Barrow (Research Nurse):
Email: [email protected]
Tel: 0191 208 3008
or visit
www.clinicaltrials.gov/ct2/show/NCT04604548?term=khenerext&draw=2&rank=1
